Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International Inc.

Kepler Capital analyst Niccolo Guido Storer maintained a Hold rating on Carel Industries SpA on November 14 and set a price target of €24.00. The c...

Kepler Capital  Keeps Their Hold Rating on Carel Industries SpA (CIG)

Traders will find all the latest earnings reports, economic data, and deals leading the stock market on Friday.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

UBS analyst Natasha Brilliant maintained a Buy rating on Carel Industries SpA today and set a price target of €26.30. According to TipRanks, Brilli...

Carel Industries SpA (CIG) Gets a Buy from UBS

Roth MKM analyst Bill Kirk maintained a Buy rating on Cresco Labs today and set a price target of $2.00. According to TipRanks, Kirk is an analyst ...

Current Quarter	$2.33	Next Quarter	$2.56
Current Year	$10.21	Next Year	$10.69
QoQ Growth	+9.9%	YoY Growth	+4.7%
3Y EPS CAGR	-70.5%	Target Price	$192.38
Consensus	Buy	Upside	+14.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRL	$167.64	+3.43%	1.34M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRL	$167.64	+3.4%	1.34M
3
4
5
6

CRL

CRL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Charles River Laboratories International Inc. Data in Excel

Get Charles River Laboratories International Inc. Data in Excel